Seven years ago, arbaclofen (STX209) was pulled from development, disappointing families around the US. Now MIT professor and FRAXA Investigator Dr. Mark Bear has founded Allos Pharma to bring it back. Dr. Bear sat down with FRAXA co-founder Katie Clapp to share the story and next steps.
FRAXA Research Foundation – Finding a Cure for Fragile X Syndrome
Accelerating Fragile X Research for Effective Treatments
